Cabozantinib Granted Fast-Track Designation for Renal Cell Carcinoma

Share this content:
FDA has granted fast-track designation to cabozantinib (Cometriq) for treatment of RCC who have received prior therapy.
FDA has granted fast-track designation to cabozantinib (Cometriq) for treatment of RCC who have received prior therapy.

The FDA has granted fast-track designation to cabozantinib (Cometriq) for treatment of patients with advanced renal cell carcinoma (RCC) who have received prior therapy, according to a release.

Developed by Exelixis, cabozantinib is currently being studied in METEOR, an ongoing phase III trial that looks at patients with metastatic RCC who experience disease progression upon treatment with at least one VEGFR tyrosine kinase inhibitor.

Subjects are randomized to either cabozantinib (60 mg) or everolimus (10 mg) daily, with primary endpoint as progression-free survival and secondary endpoint as overall survival and response rate.

RELATED: Adding More Dietary Lycopene May Help Protect Against Kidney Cancer

Exelixis is also studying the effects of cabozantinib in CELESTIAL, another phase III trial for the treatment of second-line hepatocellular carcinoma.

Cabozantinib is currently approved by the FDA for treatment of progressive, metastatic medullary thyroid cancer.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters